Extended-Release Amantadine May Improve Levodopa Dyskinesia Control

VANCOUVER — An extended-release amantadine formulation reduced levodopa-induced dyskinesia in a phase III Parkinson’s disease trial from the drug’s developer, Adamas Pharmaceuticals.

Source: Caring for the Ages - May 28, 2016 Category: Health Management Authors: M. Alexander Otto Source Type: news